MedTrace Logo

Tumor Regression Grade As Predictor of Adjuvant Therapy

NCT06710665 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-11-29

No results posted yet for this study

Summary

Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. Tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.

Conditions

  • Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG

Chemotherapy

Chemotherapy

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    collaborator OTHER

  • Quanzhou First Hospital

    collaborator OTHER

  • Fujian Medical University Union Hospital

    lead OTHER

Principal Investigators

  • Bin Zheng · Key Laboratory of Cardio-Thoracic Surgery, Fujian Medical University, Fujian Province University, Fu

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-10-01
Completion
2025-10-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06710665 on ClinicalTrials.gov